Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
J Mascarenhas - Expert Review of Hematology, 2022 - Taylor & Francis
Introduction Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by a
complex symptom profile, cytopenias, splenomegaly, and potential for leukemic progression …
complex symptom profile, cytopenias, splenomegaly, and potential for leukemic progression …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
Cytokine profiling in myeloproliferative neoplasms: overview on phenotype correlation, outcome prediction, and role of genetic variants
Among hematologic malignancies, the classic Philadelphia-negative chronic
myeloproliferative neoplasms (MPNs) are considered a model of inflammation-related …
myeloproliferative neoplasms (MPNs) are considered a model of inflammation-related …
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk …
evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk …
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses
S Verstovsek, J Gotlib, RA Mesa, AM Vannucchi… - Journal of hematology & …, 2017 - Springer
Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and
reduced survival compared with age-/sex-matched controls. This analysis evaluated the …
reduced survival compared with age-/sex-matched controls. This analysis evaluated the …
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
CN Harrison, N Schaap, AM Vannucchi… - American journal of …, 2020 - Wiley Online Library
Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2
study assessed fedratinib in patients with intermediate‐or high‐risk myelofibrosis (MF) who …
study assessed fedratinib in patients with intermediate‐or high‐risk myelofibrosis (MF) who …
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
CN Harrison, AJ Mead, A Panchal, S Fox… - Blood, The Journal …, 2017 - ashpublications.org
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-
related symptoms, as well as risks of thrombosis, hemorrhage, transformation to …
related symptoms, as well as risks of thrombosis, hemorrhage, transformation to …
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
CN Harrison, S Koschmieder, L Foltz, P Guglielmelli… - Annals of …, 2017 - Springer
Abstract Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
are myeloproliferative neoplasms (MPNs) associated with high disease burden, reduced …
are myeloproliferative neoplasms (MPNs) associated with high disease burden, reduced …
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
N Pemmaraju, H Kantarjian, K Sweet, E Wang… - Blood, 2023 - ashpublications.org
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy
with historically poor outcomes and no worldwide consensus treatment approach. Unique …
with historically poor outcomes and no worldwide consensus treatment approach. Unique …
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States
S Verstovsek, J Yu, RM Scherber, S Verma… - Leukemia & …, 2022 - Taylor & Francis
This analysis examined trends in incidence and survival among US adults with
myeloproliferative neoplasms, including essential thrombocythemia (ET; n= 14,676) …
myeloproliferative neoplasms, including essential thrombocythemia (ET; n= 14,676) …